Biofrontera (BFRI) Stock: Buy, Sell, or Hold?
BFRI - Biofrontera Inc. Common Stock
$0.80
0.00 (-0.50%)
▼
5d:
-3.61%
30d:
-31.62%
90d:
-26.61%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 11, 2026
19d
Get Alerted When BFRI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BFRI shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BFRI shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.59
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$1.61
50.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 4.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BFRI is currently trading at $0.80, which is considered oversold relative to its 30-day fair value range of $0.87 to $1.20. From a valuation perspective, the stock is trading at a discount (Forward PE: 1.9) compared to its historical average (4.3). Remarkably, the market is currently pricing in an annual earnings decline of 24.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BFRI is in a strong uptrend. The price is currently testing key support at $0.79. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.00 (+650.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BFRI is in a strong uptrend. The price is currently testing key support at $0.79. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.00 (+650.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.87 -
$1.20
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 650.0% below Wall St target ($6.00)
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.87 -
$1.20
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.79
Resistance Level
$1.01
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.86
Wall Street Target
$6.00
(+650.0%)
Revenue Growth (YoY)
32.9%
Profit Margin
-13.8%
Valuation Discount vs History
-24.2% cheaper
PE vs Historical
1.9 vs 4.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-24.2%
(market-implied from PE analysis)
1-Year Target
$0.72
(-10%)
2-Year Target
$0.65
(-19%)
3-Year Target
$0.58
(-27%)
3-Yr Target (if PE normalizes)
(PE: 2→4)
$1.35
(+69%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 1.9 to 4.3
Stabilization Target:
$1.85
(+131.1%)
PE Expansion Potential:
+131.1%
Share & Embed Analysis
Last updated: October 22, 2026 9:27 AM ET
Data refreshes hourly during market hours. Next update: 10:27 AM
Data refreshes hourly during market hours. Next update: 10:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BFRI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 59 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 50 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 47 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 61 BUY |
